Lionco Pharm Grp Co Ltd (603669) - Net Assets
Based on the latest financial reports, Lionco Pharm Grp Co Ltd (603669) has net assets worth CN¥623.24 Million CNY (≈ $91.20 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.12 Billion ≈ $164.14 Million USD) and total liabilities (CN¥498.43 Million ≈ $72.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Lionco Pharm Grp Co Ltd total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥623.24 Million |
| % of Total Assets | 55.56% |
| Annual Growth Rate | 11.9% |
| 5-Year Change | -57.48% |
| 10-Year Change | -46.96% |
| Growth Volatility | 56.69 |
Lionco Pharm Grp Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Lionco Pharm Grp Co Ltd's net assets have evolved over time, based on quarterly financial data. Check 603669 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Lionco Pharm Grp Co Ltd (2011–2025)
The table below shows the annual net assets of Lionco Pharm Grp Co Ltd from 2011 to 2025. For live valuation and market cap data, see Lionco Pharm Grp Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥620.28 Million ≈ $90.77 Million |
-19.42% |
| 2024-12-31 | CN¥769.76 Million ≈ $112.64 Million |
-17.32% |
| 2023-12-31 | CN¥931.04 Million ≈ $136.24 Million |
-17.98% |
| 2022-12-31 | CN¥1.14 Billion ≈ $166.11 Million |
-22.19% |
| 2021-12-31 | CN¥1.46 Billion ≈ $213.47 Million |
-1.42% |
| 2020-12-31 | CN¥1.48 Billion ≈ $216.55 Million |
+12.64% |
| 2019-12-31 | CN¥1.31 Billion ≈ $192.25 Million |
-4.65% |
| 2018-12-31 | CN¥1.38 Billion ≈ $201.64 Million |
+6.06% |
| 2017-12-31 | CN¥1.30 Billion ≈ $190.12 Million |
+11.10% |
| 2016-12-31 | CN¥1.17 Billion ≈ $171.13 Million |
+4.46% |
| 2015-12-31 | CN¥1.12 Billion ≈ $163.82 Million |
+199.23% |
| 2014-12-31 | CN¥374.13 Million ≈ $54.75 Million |
+6.58% |
| 2013-12-31 | CN¥351.02 Million ≈ $51.37 Million |
+48.60% |
| 2012-12-31 | CN¥236.22 Million ≈ $34.57 Million |
+83.76% |
| 2011-12-31 | CN¥128.55 Million ≈ $18.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Lionco Pharm Grp Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 803.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.12 Billion | 180.60% |
| Total Equity | CN¥620.28 Million | 100.00% |
Lionco Pharm Grp Co Ltd Competitors by Market Cap
The table below lists competitors of Lionco Pharm Grp Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unionman Technology Co. Ltd. A
SHG:688609
|
$616.06 Million |
|
Alltop Technology Co Ltd
TWO:3526
|
$616.10 Million |
|
Zhejiang Qianjiang Biochemical Co Ltd
SHG:600796
|
$616.29 Million |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
$616.59 Million |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
$615.81 Million |
|
Ramaco Resources Inc
NASDAQ:METC
|
$615.53 Million |
|
Canadian Banc Corp
TO:BK
|
$615.08 Million |
|
Wecome Intelligent Manufacturing Co. Ltd.
SHG:603070
|
$614.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lionco Pharm Grp Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 769,759,810 to 620,282,202, a change of -149,477,608 (-19.4%).
- Net loss of 193,239,351 reduced equity.
- Dividend payments of 6,591,341 reduced retained earnings.
- Other comprehensive income decreased equity by 202,575,205.
- Other factors increased equity by 252,928,290.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-193.24 Million | -31.15% |
| Dividends Paid | CN¥6.59 Million | -1.06% |
| Other Comprehensive Income | CN¥-202.58 Million | -32.66% |
| Other Changes | CN¥252.93 Million | +40.78% |
| Total Change | CN¥- | -19.42% |
Book Value vs Market Value Analysis
This analysis compares Lionco Pharm Grp Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.50x to 6.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.24 | CN¥5.91 | x |
| 2012-12-31 | CN¥0.44 | CN¥5.91 | x |
| 2013-12-31 | CN¥0.66 | CN¥5.91 | x |
| 2014-12-31 | CN¥0.70 | CN¥5.91 | x |
| 2015-12-31 | CN¥1.74 | CN¥5.91 | x |
| 2016-12-31 | CN¥1.63 | CN¥5.91 | x |
| 2017-12-31 | CN¥1.81 | CN¥5.91 | x |
| 2018-12-31 | CN¥1.94 | CN¥5.91 | x |
| 2019-12-31 | CN¥1.82 | CN¥5.91 | x |
| 2020-12-31 | CN¥1.94 | CN¥5.91 | x |
| 2021-12-31 | CN¥2.03 | CN¥5.91 | x |
| 2022-12-31 | CN¥1.58 | CN¥5.91 | x |
| 2023-12-31 | CN¥1.29 | CN¥5.91 | x |
| 2024-12-31 | CN¥1.07 | CN¥5.91 | x |
| 2025-12-31 | CN¥0.86 | CN¥5.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lionco Pharm Grp Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -59.92%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.78x
- Recent ROE (-31.15%) is below the historical average (10.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 43.37% | 20.53% | 1.11x | 1.90x | CN¥42.90 Million |
| 2012 | 40.29% | 20.32% | 1.28x | 1.54x | CN¥71.55 Million |
| 2013 | 32.70% | 23.23% | 0.85x | 1.66x | CN¥79.70 Million |
| 2014 | 40.06% | 26.00% | 1.03x | 1.50x | CN¥112.45 Million |
| 2015 | 13.37% | 27.19% | 0.41x | 1.20x | CN¥37.74 Million |
| 2016 | 13.16% | 32.16% | 0.36x | 1.15x | CN¥36.98 Million |
| 2017 | 12.39% | 16.02% | 0.61x | 1.27x | CN¥31.08 Million |
| 2018 | 13.26% | 10.94% | 0.81x | 1.50x | CN¥44.91 Million |
| 2019 | 15.34% | 12.33% | 0.85x | 1.46x | CN¥70.21 Million |
| 2020 | 10.82% | 15.99% | 0.37x | 1.84x | CN¥12.09 Million |
| 2021 | 4.52% | 8.90% | 0.29x | 1.72x | CN¥-79.98 Million |
| 2022 | -17.25% | -67.71% | 0.16x | 1.63x | CN¥-309.38 Million |
| 2023 | -16.27% | -76.97% | 0.12x | 1.74x | CN¥-244.60 Million |
| 2024 | -16.99% | -34.43% | 0.30x | 1.63x | CN¥-207.74 Million |
| 2025 | -31.15% | -59.92% | 0.29x | 1.78x | CN¥-255.27 Million |
Industry Comparison
This section compares Lionco Pharm Grp Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,415,217,854
- Average return on equity (ROE) among peers: 8.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lionco Pharm Grp Co Ltd (603669) | CN¥623.24 Million | 43.37% | 0.80x | $616.04 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $52.15 Million | 21.80% | 0.58x | $677.63 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $591.07 Million | 1.62% | 0.52x | $371.27 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $11.33 Billion | 18.40% | 0.22x | $4.77 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.68 Billion |
| Wedge Industrial Co Ltd (000534) | $505.90 Million | 6.81% | 0.17x | $1.85 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $11.30 Billion | 22.19% | 0.45x | $13.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $384.18 Million | -22.43% | 1.41x | $907.46 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $279.29 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $985.67 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.27 Billion | 5.94% | 0.48x | $3.25 Billion |
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, and other applications. The company was founded in 2003 a… Read more